A study in the New England Journal of Medicine showed treatment with an ACE inhibitor plus angiotensin-receptor blocker did not fare better than monotherapy in reducing the risk of cardiovascular events and death in patients with diabetic nephropathy. Researchers also noted a higher likelihood of hyperkalemia and acute kidney injury in the combination therapy group compared with the monotherapy arm.

Related Summaries